Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Schooner Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Schooner Capital

Schooner Capital

Operating

Schooner Capital: A Boston-based private equity firm, fostering independent thinking since 1971.

Location
Boston, MA, US
Founded
1971
Firm
Compare
Portfolio
Employees
Website

Investments

Jetcool Technologies
Jetcool Technologies

Total Raised

$36.2M

Rounds

5

Series A$17MOctober 2023
Series UnknownJune 2021
Congruity360
Congruity360

Total Raised

$25M

Rounds

2

Series UnknownJune 2023
Censinet
Censinet

Total Raised

$19.3M

Rounds

4

Series Unknown$9MJanuary 2023
Series A$7.8MApril 2019
Seed$2MSeptember 2017
Breezeway
Breezeway

Total Raised

$36.2M

Rounds

6

Series B$15MOctober 2022
Series A$8MAugust 2020
Zippity
Zippity

Total Raised

$15.1M

Rounds

7

Seed$3.3MMarch 2022
Seed$1.9MNovember 2020
Seed$3MSeptember 2019
Selux Diagnostics
Selux Diagnostics

Total Raised

$172.5M

Rounds

9

Series C$50MFebruary 2022
Series B$25MDecember 2018
Amplified Industries
Amplified Industries

Total Raised

$10M

Rounds

3

SeedJanuary 2022
Commonwealth Fusion Systems
Commonwealth Fusion Systems

Total Raised

$2B

Rounds

5

Series B$1.8BDecember 2021
Series A$84MMay 2020
Series A$115MJune 2019
MarginEdge
MarginEdge

Total Raised

$80.4M

Rounds

7

Series B$18MSeptember 2021
Cullinan Oncology
Cullinan Oncology
Public

Total Raised

$389.7M

Rounds

5

Series C$131.2MDecember 2020
Remedy Plan
Remedy Plan

Total Raised

$29.2M

Rounds

6

Series Unknown$1.5MNovember 2018
SRS Medical Systems
SRS Medical Systems

Total Raised

$5.1M

Rounds

4

Series UnknownOctober 2018
Series UnknownDecember 2017
Spotted
Spotted

Total Raised

$4.8M

Rounds

3

Series A$3.7MApril 2018
eXIthera Pharmaceuticals
eXIthera Pharmaceuticals

Total Raised

$18M

Rounds

4

Series UnknownAugust 2017
MediaSilo
MediaSilo
Acquired

Total Raised

$9.3M

Rounds

2

Series Unknown$7MFebruary 2017